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Hypertension represents a major health problem with an appalling annual toll. Despite the plethora of antihypertensive drugs,
hypertension remains resistant in a considerable number of patients, thus creating the need for alternative strategies, including
interventional approaches. Recently, catheter-based renal sympathetic denervation has been shown to be fairly safe and eﬀective
in patients with resistant hypertension. Pathophysiology of kidney function, interaction and crosstalk between the kidney and the
brain,justiﬁes the use ofrenal sympathetic denervationin the treatment of hypertension. Data from older studies haveshownthat
sympathectomy has eﬀectively lowered blood pressure and prolonged life expectancy of hypertensive patients, but at considerable
cost. Renal sympathetic denervation is devoid of the adverse eﬀects of surgical sympathectomy, due to its localized nature, is
minimallyinvasive, and provides short procedural and recovery times. This paper outlines the pathophysiological background for
renal sympathetic denervation, describes the past and the present of this interventional approach, and considers several future
potential applications.
1.Introduction
Resistanthypertension isdeﬁnedasuncontrolledbloodpres-
sure despite the use of optimal doses of three antihyper-
tensive agents, of which one is a diuretic [1–4]. Using this
deﬁnition prevalence of resistant hypertension can be as
high as 30% in some regions, but prevalence of true
resistant hypertension is most likely around 5% in organized
referral centers [2–4]. Although several factors contribute to
“resistant hypertension” (poor patient adherence, physician
inertia, inappropriate drug combinations or inadequate
dosing, drug-interaction, and secondary causes), the fact is
that a small percentage of hypertensive patients remain with
unacceptably high blood pressure levels. It has been shown
thatamajorityofpatientswith resistanthypertension andno
identiﬁablesecondarycauseshaveactivatedsympathetic ner-
vous system and increased sympathetic outﬂow (Figure 1).
The high prevalence of hypertension in the general popu-
lation renders this small percentage of patients signiﬁcant,
in terms of actual patient numbers. The above, combined
with severallimitations of drugtherapy (cost,adverse eﬀects,
polypharmacy, etc.), create the need for other therapeutic
options, such as devices and interventions.
Despite the availability of multiple medications, control
rates are still very low worldwide. Although progress has
been made in the USA and other countries, control rates
remain around 50% in the US and much lower in the rest
of the world. The present situation is reminiscent of the
40s and 50s when therapeutic options for hypertension were
limited and radical sympathectomy became popular among
hypertensionexperts.Thebeneﬁcialeﬀectsofpharmacologic
therapy shown ﬁrst by the Veteran Administration study
group [5, 6] and later conﬁrmed by many other trials made
pharmacologic therapy the preferred and only option for the
treatment of hypertension.
Surgical sympathectomy was driven to total obscurity
primarily due to serious adverse eﬀects. It should be not-
ed, however, that sympathectomy was the ﬁrst attempt to2 International Journal of Hypertension
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Figure 1: Demonstrates pathophysiologyofresistant hypertension.
Increased sympathetic outﬂow is a fundamental abnormality in
most patients.
eﬀectively confront malignant hypertension and its conse-
quences through an interventional approach [7–12]. Indeed
several studies have shown sympathectomy to be very
eﬀective in reducing blood pressure, and results were
maintained in the long term (Figure 2). Recently another
innovative approach has been used to decrease sympathetic
outﬂow using an implantable device (Rheos) to electrically
stimulate the carotid baroreceptors. Early results have shown
adequate blood pressure and heart rate reduction (Figure 3),
and feasibility studies have shown promising long-term
results [13, 14]. However long-term randomized data are
still pending.
Selective renal sympathetic denervation (RSD) [15]i s
the latest and perhaps the most interesting approach used
recently in an attempt to interrupt the inﬂuence of the
sympathetic nervous system on the kidney and systemic
hemodynamics.
The sympathetic innervation of the kidney is implicated
in the pathogenesis of hypertension through eﬀects on
rennin secretion, increased plasma rennin activity that leads
to sodium and water retention, and reduction of renal blood
ﬂow (RBF) [16, 17]. Complete bilateral renal denervation
decreases the level of blood pressure in several experimental
models, such as spontaneously hypertensive rats, DOCA
hypertensive rats, two-kidney one-clip rats, obesity-induced
hypertensive dogs, and aortic coarctation dogs [16].
In this paper we will brieﬂy summarize the role of renal
sympathetic innervation on blood pressure regulation and
discuss the past and the present of RSD in the treatment of
arterial hypertension.
2.RenalSympatheticInnervations
2.1. Eﬀerent Sympathetic Fibers. The sympathetic innerva-
tion of the kidney is achieved through a dense network of
postganglionic neurons that innervate the kidney [18, 19].
The axons of preganglionic neurons exit the thoracic and
lumbar sympathetic trunk and reach the pre- and par-
avertebralsympathetic ganglia. Renal preganglionic nerves
run alongside the renal artery and enter the hilus of the
kidney. Thereafter, they divide into smaller nerve bundles
following the blood vessels and penetrate the cortical and
juxtamedullary areas (Figure 5). Renal sympathetic nerve
activation enhances noradrenalin production for nerve end-
ings and noradrenalin spillover [20–22], while interruption
of renal sympathetic ﬁbers results in a marked decrease
of noradrenalin spillover (up to 95% [16]). When renal
sympathetic nerves are activated, b1 adrenergic receptors
enhance rennin secretion and a1 receptor activation results
in increased sodium and ﬂuid reabsorption, renal vasocon-
striction, and decrease in renal blood ﬂow.
2.2. Aﬀerent Renal Sympathetic Innervation. Aﬀerent renal
sympathetic nerves originate mostly from the renal pelvic
wall [23–25]. Mechanoreceptors respond to stretch and
chemoreceptors detect renal ischemia [16, 26]. The cell
bodiesofrenal aﬀerentnerveslie in the ipsilateral dorsal root
g a n g l i a( T 6 - L 4 ) .F r o mt h e r e ,a s c e n d i n gs i g n a l st r a v e lt ot h e
renal cardiovascular centers in the CNS. Aﬀerent renal nerve
activation promotes vasopressin and oxytocin release from
the neuro-hypophysis51. Prior renal denervation of the stim-
ulated kidney, however, attenuates these eﬀects, suggesting
thatcompleterenaldenervationeﬀectivelyinhibitsascending
aﬀerent stimuli. Overallaﬀerent sympathetic ﬁbers may have
important contribution in regulation of systemic vascular
resistance and blood pressure control. Figures 5 and 6
depict schematically the sympathetic innervations of the
kidney and the pathophysiologic role of eﬀerent and aﬀerent
ﬁbers.
3.RenalSympatheticDenervation(RSD)
3.1. Historical Perspective. Partial sympathectomy was at-
tempted more than 40 years ago in patients with malignant
hypertension. Malignant hypertension was a devastating dis-
ease with a ﬁve-year mortality rate ofalmost 100% [27], thus
interventional approaches have been tested for its treatment
given the lack of eﬀective drug therapy. Sympathectomy
was mainly applied in patients with severe or malignant
hypertension, as well as in patients with cardiovascular
deterioration despite of relatively good blood pressure
reduction by other means [7–12]. After the introduction
of antihypertensive drugs, sympathectomy was reserved for
patients who failed to respond to antihypertensive therapy
or could not tolerate it.
Total sympathectomy was impractical and poorly tol-
erated by most patients. It had to include the abdominal
organs in order to be eﬀe c t i v e ,a n di tw a st h u st e r m e d
splanchnicectomy. Sympathectomy was performed either in
one or two stages, required a prolonged hospital stay (2–4
weeks) and a long recovery period (1-2 months) and more
importantly a skilled surgeon to perform it. It was thus
performed only in a few selected centres in the USA(Boston,
Michigan, Cleveland, Rochester, Miami, and California) and
in Europe. Pioneers with signiﬁcant contribution in this
ﬁeld include Page, Craig, Peet, Isberg, Smithwick, Allen, and
Adson.International Journal of Hypertension 3
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Figure 2: Long-term blood pressure control following surgical sympathectomy.
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Figure 3: Blood pressure and heart rate reduction using barorecep-
tor stimulation therapy (BST) from 1 to 3 volts. Note that acutely
blood pressure was reduced from 210/96 to 144/66 and heart rate
from 71 to 50 beats per minute.
Sympathectomy proved to be eﬀective in reducing blood
pressure immediately postoperatively, and the results were
maintained in the long term in most patients. Sympathec-
tomy was associated with improved survival in the long run.
Notably, in a large observational study of more than 2,000
patients (1,506 splanchnicectomy), survival rates were more
Radiofrequency ablation of sympathetic fibers 
Figure 4: Sympathetic ﬁbers, both eﬀerent and aﬀerent, are found
in the adventitia of renal arteries. These ﬁbers can be ablated using
specialized catheters that deliver radiofrequency energy.
than doubled in patients undergoing sympathectomy, and
the beneﬁts were evident in all stages of hypertension [28]. A
satisfactory blood pressure response was observed in about
half of the patients that underwent splanchnicectomy.4 International Journal of Hypertension
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Figure 5: Schematic representation of sympathetic innervations of the kidney.
The two major limitations of splanchnicectomy were the
required surgical expertise and the frequent adverse events
occurringwiththisprocedure.Adverseeventswerecommon,
annoying, some of them serious, and included orthostatic
hypotension, orthostatic tachycardia, palpitations, breath-
lessness, anhidrosis, cold hands, intestinal disturbances, loss
ofejaculation,sexual dysfunction, thoracicductinjuries, and
atelectasis. The advent of eﬀective antihypertensive therapy
made surgical sympathectomy unattractive and undesirable
for most patients.
4. CurrentUse of Renal Sympathetic
Denervation(RSD)
Renal sympathetic denervation presents a major improve-
ment with several signiﬁcant advantages over the radical
sympathectomy that was performed ﬁve decades ago. It
is a localized procedure, minimally invasive, and has no
systematic side eﬀects, and the procedural and recovery
times are very short (see Figure 4). The technique was
pioneered by Sobotka, Krum, and others who performed the
ﬁrst study of catheter-based RSD [14]. The study included
50 patients with resistant hypertension, with 45 of them
fulﬁlling eligibility anatomical criteria. Renal sympathetic
ablation was achieved using a radiofrequency ablation
catheter inserted through the femoral artery and selectively
engaging the renal artery bilaterally (Symplicity, Ardian
Inc., Palo Alto, Calif, USA). This proof-of-principle trial
was carried out in patients with resistant hypertension
(i.e., systolic blood pressure ≥160mmHg on three or more
antihypertensive medications, including a diuretic). The
primary objective of the study was safety and eﬃcacy.
The primary endpoint was change in oﬃce blood pressure
at 1, 3, 6, 9, and 12 months after the procedure. Renal
angiography was done before, immediately after, and 14–30
days after procedure, and magnetic resonance angiogram 6
months after the procedure in some patients. The eﬃcacy
of RSD was conﬁrmed in a subgroup of 10 patients by the
use of noradrenaline spillover technique. Renal sympathetic
ablation resulted in impressive blood pressure reductions
that were maintained during the 12-month follow-up period
(Figure 7).Five patientsthat were ineligible forthe study due
to anatomical reasons were used as controls; blood pressure
in these patients gradually increased during the follow-up
period.International Journal of Hypertension 5
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Figure 6: Aﬀerent and eﬀerent sympathetic innervations of the kidney.
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Figure 7: Blood pressure response following bilateral renal sympa-
thetic denervation using a radiofrequency ablation catheter.
This proof-of-concept study opens new avenues in the
treatment of resistant hypertension. The study provided the
ﬁrst evidence that catheter-based ablation of renal sympa-
thetic ﬁbers is safe and eﬀective. Only two adverse eﬀects
occurred (one renal artery dissection and one femoral artery
pseudoaneurysm). These were complications related to the
percutaneous technique and not to radiofrequency ablation.
Postprocedural anatomic adverse events were evaluated by
renal angiography at one month in 18 patients and renal
magnetic resonance angiography (MRA) at six months in
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Figure 8: Noradrenalin spillover of both the right and the left
kidneys atbaselineand30 daysafter sympathetic renal denervation.
14 patients. The study is important because it demonstrates
for the ﬁrst time in humans that RSD can reduce blood
pressure in a safe way and results are sustained in the
long term. In fact follow-up data in an expanded group of
patients (N = 153) indicate that blood pressure lowering is
maintained for >2 years after the procedure with favorable
target organ consequences.
Although these results were impressive, the study created
severalconcernsandmany questionswerelefttobeexplored:
There was no proper control group, since the study was6 International Journal of Hypertension
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Figure 9: Results of microneurography before and after renal nerve ablation. Panel (a) shows the results of bilateral renal denervation, as
assessed by the radiotracer dilution method, at baseline and 30 days after the procedure. After ablation, decreases in renal norepinephrine
spillover were observed in both kidneys (48% in the left kidney and 75% in the right kidney), indicating substantial modulation of renal
sympathetic eﬀerent nerve activity after the procedure. Simultaneously, a marked reduction in whole-body sympathetic nerve activity was
apparent, with a decrease in whole-body norepinephrine spillover of 42% (b). Panel (c) shows a reduction in muscle sympathetic-nerve
activity (MSNA),as assessedin the peroneal nerve on microneurography, after bilateral renal nerve ablation,which highlightsthe possibility
that inhibition of aﬀerent renal-nerve activity may contribute to the reduction in central sympathetic drive.
not randomized or placebo (sham-operation) controlled. A
proper workup of resistant hypertensives was not performed
prior to randomization, in order to exclude patients with
white coat hypertension, poor adherence, secondary forms
or hypertension, or other correctable types of resistant
hypertension. Furthermore, predictors of blood pressure
response have not been identiﬁed, generating unavoidable
concerns when it comes to an interventional approach.
Anothermajorconcernwiththeradiofrequency-induced
renal sympathetic nerve ablation was the potential for
development of suitable substrate for renal artery stenosis
due to intimal injury. Tissue damage and ﬁbrosis have been
observed with radiofrequency ablation in other areas of the
body (i.e., left atrium for atrial ﬁbrillation, tumor ablation,
etc.). it is important to note, however, that the energy
deliveredinotherconditionsismuchhighercomparedtothe
one required for RSD, thus rendering RSD potentially harm-
less. Credence to this argument comes from the ﬁndings of
Krum et al. [14, 15]. They reported that no signs of renal
artery stenosis were observed during the six-month follow-
up period, using magnetic resonance angiography, and no
evidence of renal artery stenosis was found in the expanded
group of patients with >2 year follow-up.
Further insights into mechanisms of hypertension con-
trol through RSD were published in a recent case report of a
59-year old patient with long-standing uncontrolled hyper-
tension on a multidrug regimen [29]. In this case, baseline
renal nor-epinephrine spillover from both the left and right
kidneys, was approximately three times the normal level,
indicating increased renal sympathetic neuronal eﬀerent
activity. Bilateral renal sympathetic nerve ablation resulted
in marked reduction of blood pressure and decrease of nor-
epinephrine spillover by 48% from the left kidney and 75%
from the right kidney (Figure 8). This reduction in renal
norepinephrine spillover was associated with a 57% increase
in renal plasma ﬂow. Whole-body norepinephrine spillover
was reduced by 42%, providing evidence of aﬀerent renal
nerveinterruptionresultingindecreasedcentralsympathetic
outﬂow. Furthermore, muscle sympathetic nerve activity,
assessed by microneurography, decreased toward normal
levels at 30 days and 12 months after renal denervation
(Figure 9).
Recently a second catheter-based RSD study—the Sim-
plicity HTN-2 [30] study—was published conﬁrming the
initial results in a controlled sample. In this multicentre,
prospective, randomised trial, patients with a baseline sys-
tolic blood pressure of 160mmHg or more (≥150mmHg
for patients with type 2 diabetes) were randomly assigned to
renal denervation with previous treatment or to maintaining
previous treatment alone (control group). The primary
endpoint was change in seated systolic blood pressure at
6 months. Out of 190 patients screened for eligibility, 106
were randomized to renal denervation (n = 52) or control
(n = 54) groups. Oﬃce-based blood pressure measurements
in the renal denervation group decreased by 32/12mmHg
(baseline of 178/96mmHg, P<. 0001), whereas they did
not diﬀer from baseline in the control group (change of
1/0mmHg (21/10), baseline of 178/97mmHg, P = .77International Journal of Hypertension 7
systolic and P = .83 diastolic). Between-group diﬀerences in
blood pressure at 6 months were 33/11mmHg (P<. 0001).
At 6 months, 41 (84%) of 49 patients who underwent renal
denervation had a reduction in systolic blood pressure of
10mmHg or more, compared with 18 (35%) of 51 controls
(P<. 0001). No serious procedure-related or device-related
complications were noted, and occurrence of adverse events
did not diﬀer between groups. Results of this study are re-
assuring and take the concept one step further. Nonethe-
less concerns about long-term safety and eﬃcacy still
remain.
5.TheFutureofRSD
Certainly results of these two studies employing catheter-
based SRD open new avenues for the treatment of patients
with resistant or diﬃcult-to-control hypertension. Future
research needs to investigate whether RSD can be applied
in milder forms of hypertension, for noncompliant patients,
patients intolerant to medication, and in several other
conditions, such as hypertension with left ventricular hyper-
trophy (LVH), congestive heart failure, and chronic kidney
disease.
6.Conclusions
Resistant hypertension represents a signiﬁcant challenge in
everyday clinical practice. Catheter-based RSD represents an
innovativenewtechniquetoeﬀectivelyreducebloodpressure
in these patients. The pathophysiology of hypertension
supports the use of RSD in the treatment of many patients
with essential hypertension.
A vast amount of evidence suggests beneﬁcial eﬀects
of sympathectomy on life expectancy in patients with
severe or malignant hypertension and in the prevention of
cardiovascular complications in patients with milder forms
of hypertension.
RSD will signiﬁcantly enrich the therapeutic armamen-
tarium for hypertension treatment and control. Indeed if
RSD proves to have long-lasting beneﬁcial eﬀects, patients
would have a choice between interventional therapy or cure
of hypertension and lifelong drug therapy with associated
expense and potential side eﬀects. It may be far fetched, but,
RSDmay become in the future a viable alternative to lifelong
drug therapy.
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